Roivant Sciences Ltd.
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $8.3M-71.6% | $29.1M-11.2% | $32.7M+3.8% | $31.5M-43.0% | $55.3M |
| Cost of revenues | $1.3M+41.1% | $911K-43.0% | $1.6M-47.3% | $3.0M-66.2% | $9.0M |
| Research and development (includes $47,867, $39,780 and $32,400 of share-based compensation expense for the years ended March 31, 2026, 2025 and 2024, respectively) | $681.8M+23.9% | $550.4M+25.1% | $439.9M-3.1% | $454.1M-6.0% | $483.0M |
| Acquired in-process research and development | $0 | $0-100.0% | $26.4M-72.9% | $97.7M-30.1% | $139.9M |
| General and administrative (includes $298,297, $239,505, and $154,873 of share-based compensation expense for the years ended March 31, 2026, 2025 and 2024, respectively) | $610.5M+3.2% | $591.4M+42.1% | $416.1M+8.5% | $383.4M | — |
| Total operating expenses | $1.29B+13.2% | $1.14B+29.3% | $884.1M-5.8% | $938.3M-33.3% | $1.41B |
| Gain on sale of Telavant net assets | $0-100.0% | $110.4M-97.9% | $5.35B | $0 | — |
| Gain on litigation settlement | $770.2M | — | — | — | — |
| (Loss) income from operations | -$515.1M+48.7% | -$1.00B-122.3% | $4.50B+595.9% | -$906.8M+32.9% | -$1.35B |
| Change in fair value of investments | -$105.0M-90.3% | -$55.2M-215.0% | $48.0M+130.5% | $20.8M-76.2% | $87.3M |
| Change in fair value of liability instruments | $47.7M+402.8% | -$15.8M-133.6% | $46.8M+154.7% | $18.4M | — |
| Gain on deconsolidation of subsidiaries | -$11.0M-254.8% | -$3.1M+90.5% | -$32.8M-11.9% | -$29.3M-480.8% | -$5.0M |
| Interest income | -$178.1M+31.1% | -$258.4M-76.5% | -$146.4M-355.0% | -$32.2M-8622.0% | -$369K |
| Other (income) expense, net | -$4.0M-137.4% | $10.7M-20.9% | $13.6M+2690.5% | $486K+115.0% | -$3.2M |
| (Loss) income from continuing operations before income taxes | -$264.6M+61.2% | -$681.6M-114.9% | $4.57B+616.1% | -$885.0M+4.2% | -$923.7M |
| Income tax expense | $133.3M+176.8% | $48.2M+124.0% | $21.5M+426.8% | $4.1M+1006.2% | $369K |
| (Loss) income from continuing operations, net of tax | -$299.8M+45.0% | -$545.2M-111.7% | $4.66B+694.5% | -$784.4M+15.1% | -$924.1M |
| Income (loss) from discontinued operations, net of tax | $0-100.0% | $373.2M+218.9% | -$313.8M-39.7% | -$224.7M | $0 |
| Net (loss) income | -$397.9M-11.5% | -$356.7M-108.4% | $4.23B+479.3% | -$1.12B-20.7% | -$924.1M |
| Net loss attributable to noncontrolling interests | -$98.1M+46.9% | -$184.8M-56.9% | -$117.7M-10.6% | -$106.4M-35.0% | -$78.9M |
| Net (loss) income attributable to Roivant Sciences Ltd. | -$299.8M-74.3% | -$172.0M-104.0% | $4.35B+531.0% | -$1.01B-19.4% | -$845.3M |
| (Loss) income from continuing operations, net of tax (in dollars per share) | -$540.00+28.0% | -$750.00-113.4% | $5610.00+610.0% | -$1100.00+12.7% | -$1260.00 |
| Income (loss) from discontinued operations, net of tax (in dollars per share) | $0.00-100.0% | $510.00+234.2% | -$380.00-18.8% | -$320.00 | $0.00 |
| Net (loss) income (in dollars per share) | -$540.00-125.0% | -$240.00-104.6% | $5230.00+468.3% | -$1420.00-12.7% | -$1260.00 |
| Basic (in shares) | 693.86B-4.3% | 725.40B-7.4% | 783.25B+9.9% | 712.79B+6.4% | 669.75B |
| Diluted (in shares) | 693.86B-4.3% | 725.40B-12.7% | 831.05B+16.6% | 712.79B+6.4% | 669.75B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Roivant reports strong clinical progress with IMVT-1402 showing 72.7% ACR20 response in difficult-to-treat rheumatoid arthritis, brepocitinib granted Breakthrough Therapy Designation for cutaneous sarcoidosis, and reaches $2.25 billion settlement with Moderna
“The positive Period 1 data from the IMVT-1402 trial in D2T RA demonstrate exciting potential for a new, differentiated mechanism to treat RA patients who have failed multiple prior therapies.”
| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | 2026-05-22 | Venker Eric | President & Immunovant CEO | Sale | 200.0K | $30.27 | $6.05M | 1.61M | View | |
| 2026-04-20 | 2026-04-22 | Venker Eric | President & Immunovant CEO | Sale | 200.0K | $29.59 | $5.92M | 1.65M | View | |
| 2026-04-16 | 2026-04-20 | Gline Matthew | Director & CEO | Sale | 289.8K | $29.16 | $8.45M | 16.74M | View | |
| 2026-04-08 | 2026-04-10 | Humes Jennifer | Chief Accounting Officer | Sale | 13.5K | $28.37 | $384K | 84.2K | View | |
| 2026-03-26 | 2026-03-30 | Fitzgerald Meghan | Director | Sale | 70.0K | $27.45 | $1.92M | 43.0K | View |
Informational purposes only, not investment advice.